Human hepatitis B immunoglobulin (pH4, Chengdu Rongsheng Pharmaceuticals)
乙型肝炎人免疫球蛋白（ph4，成都蓉生）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameHuman hepatitis B immunoglobulin (pH4, Chengdu Rongsheng Pharmaceuticals)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved Indications
Approved Indications in China
Original Approved Country/Territory
Original Approved Date2012/06/27
Country/Territory
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChengdu Rongsheng Pharmaceuticals Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesChengdu Rongsheng Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A